Pay in 4 interest-free payments of $9.75 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage
including murine and rat mechanistic breast cancer models driven by MMTV–Wnt1 and a human head and neck squamouscell carcinoma model (HN30)
(2015) Cell Stem Cell 16(2):142-7
In R132H-IDH1 glioma xenografts (TS603)
RVX-208 - BET Bromodomain Inhibitor. CAS# 1044870-39-4 60428 Inhibition of SIRT1 catalytic activityRVX 208, CAS No. 1044870 39 4, also known as Apabetalone, is a potent inhibitor of BET bromodomains. RVX 208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT). RVX 208 increases the production of ApoA I in hepatocytes in vitro, and in vivo in monkeys and humans, which results in increased HDL C, but the molecular target was not previously reported. RVX 208 may be a promising new approach to the treatment of
US$ 599.93
US$ 77.60
US$ 68.78
US$ 187.65